Annual report pursuant to Section 13 and 15(d)

SCHEDULE OF REVENUE RECOGNITION (Details)

v3.24.1
SCHEDULE OF REVENUE RECOGNITION (Details) - USD ($)
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Product Information [Line Items]    
Total net revenue $ 2,532,499 $ 4,803
Health Care, Patient Service [Member]    
Product Information [Line Items]    
Total net revenue [1] 2,199,558
Histology Fees [Member]    
Product Information [Line Items]    
Total net revenue 272,660
Health Care, Other [Member]    
Product Information [Line Items]    
Total net revenue 19,324
Department of Defense Observational Studies [Member]    
Product Information [Line Items]    
Total net revenue 19,442
Other Revenues [Member]    
Product Information [Line Items]    
Total net revenue [2] $ 21,515 $ 4,803
[1] Patient services fees includes direct billing for CyPath® Lung diagnostic test.
[2] Other revenues include pre-acquisition CyPath® Lung royalty income and laboratory services.